Riskpilot← Back to searchSign inGet full accessEpimode Pharma AB
ABActiveOrg 5591873293Economic activity was not specified by tax authority · NACE 0000Est. 20180 employees
Revenue 2025
SEK 2
EBITDA margin
-408000.0%
Equity ratio
18.2%
Financial strength
Net profit 2025
SEK -9K
0 employees
| Revenue | SEK 2 | — |
| EBITDA | SEK -8K | — |
| Net profit | SEK -9K | — |
| Total assets | SEK 192K | +283% |
| Equity | SEK 35K | -20% |
| Employees | 0 | — |
Legal name
Epimode Pharma AB
Org number
5591873293
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
19 december 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva forskning, utveckling och kommersialisering av medicintekniska produkter och läkemedel.
Address
Email
te@q-surg.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | — | — | — | −6 | — | — | −8 |
| Depreciation & amort. | −0 | −0 | −0 | — | — | — | −1 |
| EBIT | 0 | 0 | 0 | −6 | 0 | 0 | −9 |
| Net financials | — | — | — | — | — | — | — |
| Profit before tax | 0 | 0 | 0 | −6 | 0 | 0 | −9 |
| Tax | −0 | −0 | −0 | — | — | — | — |
| Net profit | 0 | 0 | 0 | −6 | 0 | 0 | −9 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 50 | 50 | 50 | 50 | 50 | 50 | 192 |
| Equity | 50 | 50 | 50 | 44 | 44 | 44 | 35 |
| Long-term debt | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 0 | 0 | 0 | 6 | 6 | 6 | 157 |
| Total debt | — | — | — | 6 | 6 | 6 | 157 |
EBITDA margin
-408000.0%
This company
15.8%
Market median
-2582378% vs market
20192025
Equity ratio
18.2%
This company
38.2%
Market median
-52% vs market
20192025
Return on equity
-25.4%
This company
18.4%
Market median
-238% vs market
20192025
Net profit margin
-442700.0%
This company
8.1%
Market median
-5465532% vs market
20192025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192025
Debt / equity
4.49×
This company
0.62×
Market median
-624% vs market
20192025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-12-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Chief Auditor | Chief Auditor | 2020 | — | — |
CT Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Epimode Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Henrik Alexander Brodström | Chief Auditor | 0 companies |
| Carl Thomas Engstrand | Chief Executive Officer | 0 companies |
| Åsa Kristina Hansdotter | Board of Directors | 0 companies |
| Jens Quistgaard | Deputy Board Member | 0 companies |